Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Moderate Buy” by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $44.00.

Several analysts recently commented on INO shares. HC Wainwright reiterated a “neutral” rating and issued a $15.00 price target on shares of Inovio Pharmaceuticals in a research report on Monday, July 15th. Stephens began coverage on shares of Inovio Pharmaceuticals in a research note on Tuesday, May 14th. They set an “overweight” rating and a $20.00 target price for the company. Oppenheimer dropped their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. Finally, Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company acquired a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at approximately $82,000. Dimensional Fund Advisors LP purchased a new position in Inovio Pharmaceuticals in the second quarter worth $605,000. Cornercap Investment Counsel Inc. acquired a new stake in Inovio Pharmaceuticals in the second quarter valued at $184,000. American Century Companies Inc. boosted its position in shares of Inovio Pharmaceuticals by 62.2% during the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 12,100 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Inovio Pharmaceuticals by 5,943.0% during the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 37,857 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO opened at $6.28 on Tuesday. Inovio Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $14.75. The firm has a market capitalization of $162.72 million, a P/E ratio of -1.71 and a beta of 0.83. The company’s fifty day moving average price is $8.85 and its 200 day moving average price is $9.91.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 99.51%. During the same period last year, the company earned ($1.56) earnings per share. On average, sell-side analysts anticipate that Inovio Pharmaceuticals will post -4.54 EPS for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.